The Pharma Data

JANUARY 10, 2021

11, 2021 07:11 UTC. The VIR Seek SARS-CoV-2 Solution is a comprehensive workflow for the detection of SARS-CoV-2 on environmental surfaces that includes swabbing of environmental surfaces, RNA extraction, analysis by Reverse Transcription PCR (RT-PCR) and evaluation by an advanced algorithm.

RNA 52

RNA Virus Research 52

The Pharma Data

JANUARY 14, 2021

14, 2021 — Multifocal microvascular injury has been observed in the brain and olfactory bulbs in postmortem observation of patients who died from COVID-19 , according to a research letter published online Dec. “Our results suggest that this may be caused by the body’s inflammatory response to the virus.”

RNA 52

RNA Virus Research 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

MAY 17, 2021

2 virus and the variant first identified in South Africa. Sanofi has also entered into vaccine manufacturing partnerships to help produce the Pfizer/BioNTech, Moderna and Johnson & Johnson shots ( DID , April 13 ), and it is developing a messenger RNA-based vaccine candidate with Translate Bio.

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

PerkinElmer

JUNE 14, 2021

In October last year, remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. Remdesivir was originally developed to treat hepatitis C and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID-19. Kirschner, L.,

Virus 52

Virus RNA Vaccine Treatment 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

Drug Target Review

SEPTEMBER 25, 2024

2021 Oct 11 [cited 2024 Sep 4];13(20):5081. 2021 Apr [cited 2024 Sep 4];2(4):377–91. Preclinical studies in models of EGFR-mutated NSCLC, KRAS G12C-mutated NSCLC and colorectal cancer (CRC) demonstrated that TT125-802 prevents the development of resistance to EGFR inhibitors and KRAS G12C inhibitors, respectively. Cancers [Internet].

Small Molecule 105

Small Molecule Regulations Therapies Treatment 105

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. Changes in mutationally constrained epitopes are rare, as they can cause the virus to lose its ability to infect and replicate, essentially rendering it unable to propagate itself.

Vaccine 52

Vaccine Virus Research Immune Response 52

PLOS: DNA Science

JULY 27, 2023

The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus. emerged in late 2021. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person.

Disease 80

Disease DNA Virus RNA 80

The Pharma Data

DECEMBER 3, 2020

Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Vaccine 52

Vaccine Immune Response Virus RNA 52

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

The SARS-CoV-2 virus encodes its own protease to help process a large virally-encoded polyprotein into smaller segments that it needs for its life cycle; a protease inhibitor drug can stop that from happening. The virus uses this enzyme to snip some longer viral proteins into shorter segments for use in replication. November 5, 2021.

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

The Pharma Data

SEPTEMBER 1, 2021

Data from the study is expected in the second half of 2021. Molnupiravir (MK-4482/EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. MOVe-AHEAD Study. About Molnupiravir.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

The Pharma Data

MARCH 9, 2021

The study showed the antiviral activity of GSK’254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. These findings were presented today at the (virtual) 2021 Conference on Retroviruses and Opportunistic Infections (CROI).

Treatment 52

Treatment RNA Pharmacokinetics Virus 52

The Pharma Data

JULY 12, 2021

In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021. This press release features multimedia. View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

Drug Discovery World

OCTOBER 4, 2022

In 2021, levels of investment hit an all-time high at $22.7 As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. Cell and gene therapies.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

MARCH 11, 2021

Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. On February 22, 2021, GSK and Sanofi announced the beginning of a new Phase 2 study with an improved antigen formulation. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 18, 2020

By the second quarter of 2021, the company plans to amend or file a new emergency use request so people who think they’re infected with COVID-19 can communicate with a medical professional online through a dedicated website to arrange a prescription and overnight delivery of the test kit. “I am hopeful that it works well.”

FDA Approval 52

FDA Approval FDA Vaccine Virus 52

Drug Discovery World

SEPTEMBER 6, 2022

Unsurprisingly, oncology remains the biggest focus for cell and gene therapy developers, accounting for 52% of clinical activity in 2021, according to ARM’s Regenerative Medicine: Disrupting the Status Quo report. Cancer is king . Despite this the industry is still expanding. New indications . Carlo Russo, CEO of Genenta.? .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

DECEMBER 3, 2020

They still believe they can manufacture more than a billion doses in 2021, enough for about 500 million people. billion vaccine doses in 2021, with the 50 million shortfall for 2020 being handled as manufacturing gets going. The downgrade of this year’s 100-million-dose goal to 50 million was caused by supply-chain issues.

Vaccine 52

Vaccine Government RNA FDA 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all. 20, 2020 02:44 UTC. CAMBRIDGE, Mass.–( –( BUSINESS WIRE )– Moderna, Inc.,

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

PLOS: DNA Science

MAY 16, 2024

A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. Did it there either recombine with another virus on its own, or inspire a manipulation of another virus of a key part of the spike gene, seeding the pandemic through a “lab leak?” Work on vaccines ensued too.

Virus 93

Virus DNA RNA Vaccine 93

Drug Discovery World

AUGUST 10, 2022

CAR T cells are made by transfecting T cells with a transgene that encodes the CAR protein using either a virus, a transposon system, or mRNA. Unlike qPCR, which requires users to generate a standard curve to estimate the concentration of DNA or RNA in a sample, ddPCR technology quantifies nucleic acids directly.

Therapies 246

Therapies Virus Treatment Engineering 246

The Pharma Data

NOVEMBER 16, 2020

Since early January, we have chased this virus with the intent to protect as many people around the world as possible. I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus. CAMBRIDGE, Mass.–(BUSINESS

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. “While much more remains to be done to make HIV history, today’s milestone reminds us how far medical innovation has come since the first reported cases of the virus almost 40 years ago.” In the U.S.,

FDA Approval 52

FDA Approval Treatment RNA FDA 52

Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Small Molecule 52

Codon

JUNE 25, 2024

Proteins are colored blue and RNA molecules are colored orange and yellow. For a 2021 paper, researchers at the California Institute of Technology estimated how long it would take E. RNA and proteins comprise each ribosome, but the cell synthesizes these two biomolecules at different rates. Nature Microbiology (2021).

DNA 70

DNA RNA Laboratories Engineering 70

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

The Pharma Data

NOVEMBER 1, 2021

Rice University researchers have introduced an online portal to help researchers screen COVID-19 drug candidates that might attack specific proteins of the SARS-CoV-2 virus. Understanding these structures allows researchers to find binding partners that could, ideally, deactivate the virus. Computers in Biology and Medicine, 2021.

Virus 52

Virus RNA Engineering Drugs 52

Codon

AUGUST 28, 2024

It is relatively straightforward to detect the first threat―creating a virus from scratch using synthetic DNA—by searching for small fragments of known viral DNA sequences in a customer’s order. This incident spurred new laws to restrict the sale of bacteria or viruses. Journalists gather outside No.

DNA 80

DNA Bioinformatics Virus Government 80

The Pharma Data

JANUARY 21, 2021

22, 2021 — Everyone has heard the scary reports about the new, more infectious coronavirus variants that are circulating in countries around the world, but scientists aren’t pushing the panic button at this point. “The spike protein is needed to bind to the cell, to allow the virus to enter,” Salvatore explained.

Vaccine 52

Vaccine Virus Immune Response RNA 52

PLOS: DNA Science

JUNE 29, 2023

A report in Nature from 2021 described the cell types in an aborted gastrula, two weeks post-fertilization. An approach called single-cell transcriptomics is widely used to study gene expression by identifying the messenger RNAs (mRNAs) that a single cell produces. The technique is called “RNA-Seq” for short.

RNA 82

RNA DNA Bioethics Research 82

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Codon

APRIL 2, 2023

Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q). By combining this new variant with standard sequencing methods, it’s possible to identify RNA modifications in a really simple way. Nucleic Acids Research. Communications Biology.

DNA 52

DNA RNA Engineering Licensing 52